Literature DB >> 32339327

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame.

Kimberly M Thompson1, Dominika A Kalkowska1.   

Abstract

The Global Polio Eradication Initiative (GPEI) partners engaged modelers during the past nearly 20 years to support strategy and policy discussions and decisions, and to provide estimates of the risks, costs, and benefits of different options for managing the polio endgame. Limited efforts to date provided insights related to the validation of the models used for GPEI strategy and policy decisions. However, modeling results only influenced decisions in some cases, with other factors carrying more weight in many key decisions. In addition, the results from multiple modeling groups do not always agree, which supports selection of some strategies and/or policies counter to the recommendations from some modelers but not others. This analysis reflects on our modeling, and summarizes our premises and recommendations, the outcomes of these recommendations, and the implications of key limitations of models with respect to polio endgame strategy. We briefly review the current state of the GPEI given epidemiological experience as of early 2020, which includes failure of the GPEI to deliver on the objectives of its 2013-2018 strategic plan despite full financial support. Looking ahead, we provide context for why the GPEI strategy of global oral poliovirus vaccine (OPV) cessation to end all cases of poliomyelitis looks infeasible given the current state of the GPEI and the failure to successfully stop all transmission of serotype 2 live polioviruses within four years of the April-May 2016 coordinated cessation of serotype 2 OPV use in routine immunization.
© 2020 The Authors. Risk Analysis published by Wiley Periodicals LLC on behalf of Society for Risk Analysis.

Entities:  

Keywords:  dynamic modeling; eradication; oral poliovirus vaccine; polio

Mesh:

Substances:

Year:  2020        PMID: 32339327      PMCID: PMC7983882          DOI: 10.1111/risa.13484

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  75 in total

1.  Evaluation of response scenarios to potential polio outbreaks using mathematical models.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens; Mark A Pallansch
Journal:  Risk Anal       Date:  2006-12       Impact factor: 4.000

Review 2.  Outbreaks of paralytic poliomyelitis, 1976-1995.

Authors:  P A Patriarca; R W Sutter; P M Oostvogel
Journal:  J Infect Dis       Date:  1997-02       Impact factor: 5.226

Review 3.  Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Authors:  Radboud J Duintjer Tebbens; Marita Zimmermann; Mark A Pallansch; Kimberly M Thompson
Journal:  Food Environ Virol       Date:  2017-07-07       Impact factor: 2.778

4.  Modeling options to manage type 1 wild poliovirus imported into Israel in 2013.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Itamar Grotto; Lester M Shulman; Emilia Anis; Steven G F Wassilak; Mark A Pallansch; Kimberly M Thompson
Journal:  J Infect Dis       Date:  2014-12-10       Impact factor: 5.226

Review 5.  Eradication versus control for poliomyelitis: an economic analysis.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Lancet       Date:  2007-04-21       Impact factor: 79.321

6.  Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination.

Authors:  Dominika A Kalkowska; Radboud J Duintjer Tebbens; Mark A Pallansch; Stephen L Cochi; Steven G F Wassilak; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2015-02-18       Impact factor: 3.090

7.  Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

8.  How should we prepare for an outbreak of reintroduced live polioviruses?

Authors:  Kimberly M Thompson; Radboud J Duintjer Tebbens
Journal:  Future Virol       Date:  2017-01-20       Impact factor: 1.831

9.  Insights From Modeling Preventive Supplemental Immunization Activities as a Strategy to Eliminate Wild Poliovirus Transmission in Pakistan and Afghanistan.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-03-06       Impact factor: 4.000

10.  Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.

Authors:  Radboud J Duintjer Tebbens; Lee M Hampton; Kimberly M Thompson
Journal:  BMC Infect Dis       Date:  2018-04-10       Impact factor: 3.090

View more
  9 in total

Review 1.  Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Stephen L Cochi; Stephanie D Kovacs; Steven G F Wassilak; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-07-06       Impact factor: 4.000

2.  Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.

Authors:  Dominika A Kalkowska; Kimberly M Thompson
Journal:  Risk Anal       Date:  2021-02       Impact factor: 4.000

3.  Disease Surveillance Investments and Administration: Limits to Information Value in Pakistan Polio Eradication.

Authors:  Ryan P Scott; Alison C Cullen; Guillaume Chabot-Couture
Journal:  Risk Anal       Date:  2020-08-21       Impact factor: 4.000

4.  Polio eradication: what kind of world do we want?

Authors:  Kimberly M Thompson
Journal:  Lancet Infect Dis       Date:  2021-10-11       Impact factor: 25.071

5.  Polio health economics: assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Kamran Badizadegan
Journal:  Gates Open Res       Date:  2022-02-03

6.  Vaccines and the social amplification of risk.

Authors:  Heidi J Larson; Leesa Lin; Rob Goble
Journal:  Risk Anal       Date:  2022-05-14       Impact factor: 4.302

7.  Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.

Authors:  Dominika A Kalkowska; Mark A Pallansch; Amanda Wilkinson; Ananda S Bandyopadhyay; Jennifer L Konopka-Anstadt; Cara C Burns; M Steven Oberste; Steven G F Wassilak; Kamran Badizadegan; Kimberly M Thompson
Journal:  Risk Anal       Date:  2020-11-10       Impact factor: 4.000

8.  Potential Future Use, Costs, and Value of Poliovirus Vaccines.

Authors:  Kimberly M Thompson; Dominika A Kalkowska
Journal:  Risk Anal       Date:  2020-07-09       Impact factor: 4.000

Review 9.  A Health Economic Analysis for Oral Poliovirus Vaccine to Prevent COVID-19 in the United States.

Authors:  Kimberly M Thompson; Dominika A Kalkowska; Kamran Badizadegan
Journal:  Risk Anal       Date:  2020-10-20       Impact factor: 4.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.